60 Degrees Pharmaceuticals (SXTP) Non-Current Deffered Revenue (2022)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Non-Current Deffered Revenue of $255000.0 for Q4 2022.
60 Degrees Pharmaceuticals (SXTP) Non-Current Deffered Revenue (2022) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Non-Current Deffered Revenue for 1 consecutive years, with $255000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Non-Current Deffered Revenue changed N/A year-over-year to $255000.0; the TTM figure through Dec 2022 stood at $255000.0 (changed N/A YoY), while the FY2022 annual figure was $255000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was little changed at $255000.0 in Q4 2022 per SXTP's latest filing.
- Across five years, Non-Current Deffered Revenue topped out at $255000.0 in Q4 2022 and bottomed at $255000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 255,000.00 |